DexCom (DXCM) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

DexCom

NasdaqGS•Healthcare•Medical Devices

$87.93+0.59(0.01%)After hours

Market Cap

$34.15B

P/E

34.2x

P/S

6.9x

P/B

13.0x

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

How this company scores

ExcellentMetricSide Score: 90/100

Strongest: Profitability (25/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability25/25

Growth25/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality25/25

Strengths

Growing revenueRising free cash flowStrong marginsHigh ROE

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 34.2x5y range 25.6x – 339.1x

Currently below its 20-quarter median.

P/S · 6.9x5y range 4.9x – 22.8x

Currently below its 20-quarter median.

P/B · 13.0x5y range 8.1x – 24.7x

Price & Volume

Market Cap $34.15B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $4.97B
Q. Revenue: $1.31B
TTM EBITDA: $1.40B
TTM Op. Income: $1.14B
Q. Op. Income: $318.30M
TTM Net Income: $999.70M
Q. Net Income: $249.10M
EPS: $0.65
Shares Out.: $382.20M

$4.97B in TTM revenue grew 15.5% YoY, reaching $1.31B last quarter. TTM EBITDA of $1.40B and TTM operating income of $1.14B show growth is flowing through to the bottom line. TTM net income of $999.70M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 63.4%
EBITDA Margin: 29.5%
Op. Margin: 24.3%
Net Margin: 19.0%

Op. margin of 24.3% is up 6.0% YoY — cost efficiency is improving. Net margin at 19.0% and gross margin of 63.4% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 32% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 34.2x
P/S Ratio: 6.9x
P/B Ratio: 13.0x

At 34.2x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 6.9x and P/B of 13.0x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 43% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $6.46B
Cash: $1.10B
Long-Term Debt: N/A
Book Value: $2.62B
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $269.20M
TTM Free Cash Flow: $1.41B
FCF Margin: 28.3%
FCF / Net Income: 1.4

TTM FCF of $1.41B on $269.20M in operating cash flow. The FCF / Net Income ratio of 1.4x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 146% — a weakening trend.